Cited 95 time in
Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Young Hee | - |
| dc.contributor.author | Kim, Yoon Sook | - |
| dc.contributor.author | Roh, Gu Seob | - |
| dc.contributor.author | Choi, Wan Sung | - |
| dc.contributor.author | Cho, Gyeong Jae | - |
| dc.date.accessioned | 2022-12-27T01:56:06Z | - |
| dc.date.available | 2022-12-27T01:56:06Z | - |
| dc.date.issued | 2012-02 | - |
| dc.identifier.issn | 1755-375X | - |
| dc.identifier.issn | 1755-3768 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/22375 | - |
| dc.description.abstract | Purpose: Vessel leakage and loss of pericytes are early signs of diabetic retinopathy (DR), which leads to vision loss. Upregulation of the vascular endothelial growth factor (VEGF) during diabetes plays a key role in mediating these vascular lesions. The aim of this study is to investigate the effects of resveratrol, a natural plant-derived phytoalexin, on vascular damage and VEGF induction in mouse retinas of early diabetes. Methods: Diabetes was induced in C57BL/6 mice by five consecutive-intraperitoneal injections of 55 mg/kg of streptozotocin (STZ). Animals injected with buffer only were used as controls. Beginning 1 month after the fifth injection of STZ or buffer, 20 mg/kg of resveratrol was administered by oral gavage daily for 4 weeks to diabetic and control mice, and all mice were killed 2 months after the injections. We assessed vessel leakage, pericyte loss and VEGF protein expression in mouse retinas of 2-month diabetes compared with controls with or without resveratrol treatment. Results: Diabetes led to increase vessel leakage, pericyte loss and VEGF protein level in the mouse retinas compared with controls; however, these changes were effectively blocked by resveratrol treatment. Conclusion: Our data suggest that resveratrol is effective to decrease vascular lesions and VEGF induction in mouse retinas of early diabetes. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Wiley-Blackwell | - |
| dc.title | Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1111/j.1755-3768.2011.02243.x | - |
| dc.identifier.scopusid | 2-s2.0-84856517048 | - |
| dc.identifier.wosid | 000299624600006 | - |
| dc.identifier.bibliographicCitation | Acta Ophthalmologica, v.90, no.1, pp E31 - E37 | - |
| dc.citation.title | Acta Ophthalmologica | - |
| dc.citation.volume | 90 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | E31 | - |
| dc.citation.endPage | E37 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Ophthalmology | - |
| dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
| dc.subject.keywordAuthor | diabetic retinopathy | - |
| dc.subject.keywordAuthor | early diabetes | - |
| dc.subject.keywordAuthor | pericyte loss | - |
| dc.subject.keywordAuthor | resveratrol | - |
| dc.subject.keywordAuthor | retina | - |
| dc.subject.keywordAuthor | vascular endothelial growth factor | - |
| dc.subject.keywordAuthor | vascular lesions | - |
| dc.subject.keywordAuthor | vessel leakage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
